ArticleSignal transduction and targeted therapy

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials.

Wen-Ying Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.